New hope for tough pancreatic cancer: targeted drug combo enters final testing phase
NCT ID NCT07232875
First seen Nov 18, 2025 · Last updated May 24, 2026 · Updated 25 times
Summary
This study tests a new drug (HRS-4642) combined with chemotherapy for people with advanced pancreatic cancer that has a specific gene change called KRAS G12D. About 588 participants will receive either the new drug plus chemo or a placebo plus chemo. The goal is to see if the new combination helps people live longer or keeps the cancer from growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS G12D-MUTANT ADVANCED OR METASTATIC PANCREATIC CANCER IN THE FIRST-LINE SETTING are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200127, China
Contact
Conditions
Explore the condition pages connected to this study.